In our previous scientific article, we presented an overview of hemangiomas, which highlighted the Mulliken typing of hemangioma-like diseases: true hemangiomas (hereafter referred to as hemangiomas) and vascular malformations. Hemangiomas and vascular malformations are two lesions that are completely different in nature. There are completely different clinical manifestations, courses and regressions. I will now focus on the treatment ideas for hemangiomas. Do hemangiomas need to be treated or not? Of course it does. So, the question arises, how to treat it? First, is the lesion a hemangioma or a vascular malformation? Hemangioma is a benign tumor mostly found in infants and children, and most of them can subside on their own, while vascular malformation is a developmental abnormality of vascular structure, mostly found in adolescence, and does not subside on its own. This differential diagnosis directly determines our treatment path: conservative observation or aggressive intervention. For some cases where the differential diagnosis is difficult, we can also use ultrasound, MR or even pathological examination to help clarify the diagnosis. Second, should we intervene medically to treat? Infantile hemangioma is usually self-limiting and can be divided into 3 stages: proliferation, stabilization and regression. They usually appear 1 to 2 weeks after birth, enter a rapid proliferation phase 1-2 months after birth, stop growing 6-12 months after birth, and enter a slow self-resolving phase 1-5 years later. According to the literature, by the age of 5 years, more than 50% of hemangiomas have completely regressed, and by the age of 9 years, 90% have completely regressed, with the longest regression lasting until the age of 12 years. Eventually, 20% to 40% of children may have residual skin changes. Therefore, for most patients, hemangiomas are only an aesthetic problem and can be conservatively observed; for the few patients who affect function, or even in a very small number of cases, a life-threatening condition, active interventional treatment is required. For infantile hemangiomas, the decision to intervene or not is determined by three main factors: the site of the lesion; the age of the child; and the size of the lesion. The site of the lesion is of first importance for the choice of treatment. If the lesion is located around a vital organ, affecting the normal growth, development and function of the organ, or even endangering life, it needs to be treated aggressively. The age of the patient at the time of consultation determines the degree of aggressive treatment measures. If the child is in the proliferative phase at the time of presentation, aggressive therapeutic intervention is usually used to avoid excessive growth of the lesion. If the child is already in the stable or receding phase at the time of presentation, treatment should be relatively conservative; all treatments have more or less side effects, and overtreatment may be harmful. The size of the lesion is also a reference factor in treatment. Large hemangiomas can cause tremendous psychological stress to the parents; at the same time, large hemangiomas tend to leave significant scarring after receding, so this type of hemangioma should also be treated actively. In addition, there are very few infant hemangiomas that may produce some serious complications, such as thrombocytopenia or heart failure, which must be treated aggressively.